EVANSTON, Ill., Dec 18, 2017 –Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline. The financing was led by Bain Capital Life Sciences. Additional new investors include Adage Capital, Agent Capital, HBM Healthcare Investments, Nan … Continue reading Aptinyx Raises $70 Million in Series B Financing